Pilaralisib analogue

SKU: orb1305574

Description

This compound is a selective, reversible inhibitor targeting the class I PI3K isoforms α, δ, and γ. It is a research tool used in vitro and in vivo to study PI3K pathway biology in areas such as oncology and immunology.

Research Area

Cell Biology, Molecular Biology, Signal Transduction

Images & Validation

−

Key Properties

−

CAS Number	956958-53-5
MW	448.52
Purity	99.46%
Formula	C₂₁H₁₆N₆O₂S₂
SMILES	Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1
Target	Apoptosis,PI3K,DNA-PK
Solubility	H2O:< 1 mg/mL (insoluble or slightly soluble);DMSO:22.45 mg/mL (50.05 mM);Ethanol:< 1 mg/mL (insoluble or slightly soluble);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.46 mM)

Bioactivity

−

Target IC50	PI3Kγ:23 nM\|PI3Kβ:383 nM\|PI3Kα:39 nM\|PI3Kδ:36 nM
In Vivo	At a concentration of 20 μM, XL147 induces cell death and leads to dose-dependent inhibition of PI3K. Treatment with XL147 reduces the levels of cell cycle proteins D1 and pRB and increases the level of CDK inhibitor p27KIPI, without detectable changes in the levels of total or cleaved poly(ADP-ribose) polymerase (PARP). Furthermore, XL147 treatment results in a dose-dependent decrease in pAKTS473/T308 and pS6S240/244. As a selective and reversible inhibitor of PI3K, XL147 exhibits an IC50 of 40 nM against p110α, acting as an ATP competitive inhibitor. In a set of HER2-overexpressing human breast cancer cell lines, XL147 treatment abolishes AKT and S6 phosphorylation but also induces the expression and phosphorylation of HER3 and other RTKs. In HER2+ cells, the combination of XL147 with siRNA against HER3 or HER2 inhibitors like trastuzumab or lapatinib enhances XL147-induced cell death and inhibition of pAKT and pS6. Read more...
In Vitro	Treatments were administered to thymus-deficient mice bearing BT474 xenografts, randomly utilizing XL147, lapatinib, trastuzumab, or a combination of XL147 with each HER2 antagonist. Every single-agent therapy significantly inhibited tumor growth, with the combination therapy proving substantially more effective than any drug used alone. The combined use of XL147 and trastuzumab exhibited a notably higher suppression of pHER3 compared to other treatments. Among all three single agents, XL147 uniquely demonstrated a statistically significant inhibition of nuclear pAKT levels, with no detectable change in cytoplasmic pAKT levels. Read more...
Cell Research	Cells including BT474, HCC1937 et al. are seeded in 100-mm dishes in media containing 2.5% FBS with or without XL147. After 3 days, detached and adherent cells are pooled, xed, and labeled with propidium iodide by using the APO-BrdU kit. Labeled cells are analyzed using the Becton Dickinson FACSCalibur system. (Only for Reference) Read more...

Storage & Handling

−

Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

SAR245408, SAR-245408, SAR 245408, Phosphoinositide 3-kinase, PI3Kδ, PI3Kγ, PI3Kβ, PI3Kα, PI3K, Pilaralisib analogue, XL147 analogue, inhibit, Inhibitor, Apoptosis, DNA-PK, DNAPK

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Compound Identifiers

PubChem CID

1893730 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols